Dietary folate and folylpolyglutamate synthetase activity in normal and neoplastic murine tissues and human tumor xenografts

Biochemical Pharmacology

Volumn 52, Issue 9, 1996, Pages 1477-1479

  Gates, Susan B ^a   Worzalla, John F ^a   Shih, Chuan ^a   Grindey, Gerald B ^a   Mendelsohn, Laurane G ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

dietary folate; folylpolyglutamate synthetase

Indexed keywords

FOLIC ACID; FOLIC ACID ANTAGONIST; FOLYLPOLYGLUTAMATE SYNTHASE; GLUTAMIC ACID; LOMETREXOL; RADIOISOTOPE; TISSUE EXTRACT; TUMOR EXTRACT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GRAFT; CONTROLLED STUDY; DIETARY INTAKE; ENZYME ACTIVITY; ENZYME SUBSTRATE; FOLATE METABOLISM; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MOUSE; NEOPLASM; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS CARCINOMA; PRIORITY JOURNAL; TISSUE DISTRIBUTION; XENOGRAFT;

ANIMALS; DIET; FEMALE; FOLIC ACID; FOLIC ACID ANTAGONISTS; HUMANS; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PEPTIDE SYNTHASES; SUBSTRATE SPECIFICITY; TETRAHYDROFOLATES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0030575935     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00554-0     Document Type: Article

References (18)

1. 1. Schmitz JC, Grindey GB, Schultz RM and Priest DG, Impact of dietary folic acid on reduced folates in mouse plasma and tissues. Biochem Pharmacol 48: 319-325, 1994.
2. 2. Ward GJ and Nixon PF, Modulation of pteroylpolyglutamate concentration and length in response to altered folate nutrition in a comprehensive range of rat tissues. J Nutr 120: 476-484, 1990.
3. 3. Gates SB, Mendelsohn LG, Shackelford KA, Habeck LL, Kursar JD, Gossett LS, Worzalla JF, Shih C and Grindey GB, Characterization of folate receptor from normal and neoplastic murine tissue: Influence of dietary folate on folate receptor expression. Clin Cancer Res 2: 1135-1141, 1996.
4. 4. Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, Ungerleider JS, Emerson WA, Tormey DC, Glick JH, Veeder MH and Mailliard JA, Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322: 352-358, 1990.
5. 5. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH and Newell DR, Clinical pharmacokinetics of the antipurine antifolate (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolic acid (lometrexol) administered with an oral folic acid supplement. Clin Cancer Res 1: 1479-1486, 1995.
6. 6. McBurney MW and Whitmore GF, Isolation and biochemical characterization of folate deficient mutants of Chinese hamster cells. Cells 2: 173-182, 1974.
7. 7. Pizzorno G, Sokoloski JA, Cashmore AR, Moroson BA, Cross AD and Beardsley GP, Intracellular metabolism of 5,10-dideazatetrahydrofolic acid in human leukemia cell lines. Mol Pharmacol 39: 85-89, 1991.
8. 8. Jackman AL, Taylor GA, Gibson W, Kimbell R, Brown M, Calvert AH, Judson IR and Hughes LR, ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: A new agent for clinical study. Cancer Res 51: 5579-5586, 1991.
9. 9. van der Wilt CL, Cloos J, de Jong M, Pinedo HM and Peters GJ, Screening of colon tumor cells and tissues for folylpolyglutamate synthetase activity. Oncol Res 7: 317-321, 1995.
10. 10. van der Laan BF, Jansen G, Kathmann GAM, Westerhof GR, Schornagel JH and Hordijk GJ, In vitro activity of novel antifolates against human squamous carcinoma cell lines of the head and neck with inherent resistance to methotrexate. Int J Cancer 51: 909-914, 1992.
11. 11. Lark RH, Smith AK and Kamen BA, Should patients receiving anti-folates be treated with folic acid first? A rationale based upon studies of folylpolyglutamate synthetase. Cancer Res Therapy Control 4: 11-16, 1994.
12. 12. Habeck LL, Mendelsohn LG, Shih C, Taylor EC, Colman PD, Gossett LS, Leitner TA, Schultz RM, Andis SL and Moran RG, Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 48: 326-333, 1995.
13. 13. Schultz RM, Merriman RL, Toth JE, Zimmerman JE, Hertel LW, Andis SA, Dudley DE, Rutherford PG, Tanzer LR and Grindey GB, Evaluation of new anticancer agents against the M1A PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5: 223-228, 1993.
14. 14. Moran RG and Colman PD, Mammalian folyl polyglutamate synthetase: Partial purification and properties of the mouse liver enzyme. Biochemistry 23: 4580-4589, 1984.
15. 15. Jansen G, Schornagel JH, Kathmann I, Westerhof GR, Hordijk G-J and van der Laan B, Measurement of folylpolyglutamate synthetase activity in head and neck squamous carcinoma cell lines and clinical samples using a new rapid separation procedure. Oncol Res 4: 299-305, 1992.
16. 16. Pohland RC, Alati T, Lantz RJ and Grindey GB, Whole-body autoradiographic dispostion and plasma pharmacokinetics of 5,10-dideazatetrahydrofolic acid in mice fed folic acid-deficient diet or regular diets. J Pharm Sci 83: 1396-1399, 1994.
17. 14C-lometrexol and its thiophene analogue in murine liver and C3H mammary tumor. Proc Am Assoc Cancer Res 36: 378, 1995.
18. 18. Alati T, Worzalla JF, Shih C, Bewley JR, Lewis S, Moran RG and Grindey GB, Augmentation of the therapeutic activity of lometrexol [(6-R)5,10-dideazatetrahydrofolate] by oral folic acid. Cancer Res 56: 2331-2335, 1996.